ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,032.38
0.56%
US Tech 100
20,389.60
0.88%
Dow Jones
44,910.65
0.42%
Brent Oil
71.98
-0.08%
Bitcoin
96,408.07
-1.10%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. OKYO Pharma Ltd (OKYO)

  7. OKYO Pharma Ltd (OKYO) News

OKYO

OKYO Pharma (OKYO)

OKYO Pharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OKYO
DateTimeSourceHeadlineSymbolCompany
11/26/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
11/26/20247:00AMGlobeNewswire Inc.OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology ConferenceNASDAQ:OKYOOKYO Pharma Ltd
10/30/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
10/30/20247:00AMGlobeNewswire Inc.OKYO Pharma to Present at International Tear Film and Ocular Surface Society ConferenceNASDAQ:OKYOOKYO Pharma Ltd
10/23/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
10/23/20247:00AMGlobeNewswire Inc.OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
10/16/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
10/16/20247:00AMGlobeNewswire Inc.OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
09/10/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
09/10/20247:00AMGlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
09/05/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
09/05/20247:00AMGlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
08/27/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
08/27/20247:00AMGlobeNewswire Inc.OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
08/23/20249:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
08/23/20249:00AMGlobeNewswire Inc.OKYO Pharma CEO Interview to Air on Bloomberg TVNASDAQ:OKYOOKYO Pharma Ltd
08/23/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
08/23/20247:00AMGlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
08/21/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
08/21/20247:00AMGlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
08/15/20241:21PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
08/15/202412:13PMGlobeNewswire Inc.OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:OKYOOKYO Pharma Ltd
08/13/20244:30PMEdgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:OKYOOKYO Pharma Ltd
08/06/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
08/06/20247:00AMGlobeNewswire Inc.OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of UseNASDAQ:OKYOOKYO Pharma Ltd
07/31/20245:00PMEdgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:OKYOOKYO Pharma Ltd
07/11/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
07/11/20247:00AMGlobeNewswire Inc.OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101NASDAQ:OKYOOKYO Pharma Ltd
07/10/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
07/10/20247:00AMGlobeNewswire Inc.OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
 Showing the most relevant articles for your search:NASDAQ:OKYO

Your Recent History

USOTC
WDLF
Decentral Life (PK)
AMEX
KULR
KULR Technology
USOTC
IQST
iQSTEL (QX)
USOTC
RNVA
Rennova Health (CE)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
QSEP
QS Energy (PK)
USOTC
ERHE
ERHC Energy (CE)
NYSE
IONQ
IonQ
NASDAQ
SMCI
Super Micro Computer
USOTC
BIEL
Bioelectronics (PK)
USOTC
HMBL
HUMBL (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
NASDAQ
FCEL
FuelCell Energy
COIN
XRPUSD
Ripple
USOTC
ASII
Accredited Solutions (PK)
USOTC
HIRU
Hiru (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 50%* for Ultimate Trader

1 year 30%, 2 years 40% and *3 years 40%

*Across 3 years $3395.52 only $1697.76